because both dose intensity and scheduling are known to affect drug activity , the lv/5-fu combination was evaluated in the preclinical cd8f1 murine model of advanced first-passage spontaneous breast tumors using the same dose ( at mtd ) and schedule for 5-fu alone and in the lv/5-fu combination arm .
C1458155
the
C0016360
lv/5-fu